Total posterior quadrant disconnection for drug-resistant epilepsy in children

Hao Yu1, Chang Liu1, Yu Sun1

  • 1Pediatric Epilepsy Center, Peking University First Hospital, Beijing, China.

Epilepsia Open
|September 19, 2024
PubMed

Insights

Total posterior quadrant disconnection (PQD) surgery effectively controlled seizures in 70.5% of pediatric patients with drug-resistant epilepsy (DRE). Postoperative outcomes were favorable, with no deaths or severe complications, and developmental improvements were noted.

Area of Science:

  • Pediatric Neurosurgery
  • Epilepsy Surgery
  • Developmental Neuroscience

Background:

  • Drug-resistant epilepsy (DRE) in children poses significant challenges to neurological development and quality of life.
  • Surgical interventions like posterior quadrant disconnection (PQD) are considered for intractable DRE with structural abnormalities.
  • Limited data exists on the efficacy and developmental impact of total PQD in pediatric populations.

Purpose of the Study:

  • To evaluate seizure outcomes following total PQD in children with DRE.
  • To identify prognostic factors influencing seizure control and developmental trajectories post-surgery.
  • To assess changes in developmental levels after total PQD surgery.

Main Methods:

  • Retrospective analysis of clinical data from 61 pediatric patients undergoing total PQD for DRE.
  • Assessment of seizure outcomes using Engel's classification.
  • Evaluation of developmental changes using Griffiths Mental Development Scales-China (GMDS-C) pre- and post-surgery.
  • Correlation analysis of preoperative data, surgical factors, and developmental outcomes.

Main Results:

  • 70.5% of pediatric patients achieved seizure freedom postoperatively.
  • Univariate and multivariate analyses identified interictal electroencephalogram (EEG) and acute postoperative seizures (APOS) as significant predictors of seizure prognosis.
  • Significant correlations were found between preoperative developmental levels and epilepsy characteristics (duration, frequency, EEG, FDG-PET).
  • Postoperative GMDS-C scores improved, while developmental quotients remained stable.

Conclusions:

  • Total PQD surgery is an effective treatment for pediatric DRE with structural posterior quadrant abnormalities, leading to seizure control without neurological deterioration.
  • Interictal EEG abnormalities and APOS are important prognostic indicators but not absolute contraindications for surgery.
  • Thorough preoperative assessment and timely surgical intervention are crucial for optimizing outcomes in pediatric epilepsy surgery.
Abstract

Related Concept Videos

Arteries of the Lower Limbs01:24

Arteries of the Lower Limbs

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
181
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
341
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
149
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
341
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
292
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
266